In this episode, listen to Matthew S. Davids, MD, MMSc​, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:

• Contemporary treatment paradigms for patients with CLL
• Safety and efficacy of current regimens
• Molecular testing, including when and how to test for BTK inhibitor resistance
• Considering BTK inhibitor resistance when sequencing therapy

Program faculty:

Matthew S. Davids, MD, MMSc​
Associate Professor of Medicine​
Harvard Medical School​
Leader, Lymphoma Program​
Dana-Farber/Harvard Cancer Center​
Director of Clinical Research​
Division of Lymphoma​
Dana-Farber Cancer Institute​
Boston, Massachusetts​​

Lindsey Roeker, MD​
Assistant Attending​
CLL Program Director​
Department of Medicine​
Memorial Sloan Kettering Cancer Center​
New York, New York

Resources:
To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:

• Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLC
• Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases
• Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLC
• The global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC
  

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:

• Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC
• Long-term safety observations for crizotinib and entrectinib
• CNS activity of entrectinib and repotrectinib in patients with brain metastases
• Repotrectinib activity in ROS1-TKI resistance mutations
  

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.